Maxim Group analyst Anthony Vendetti reiterated a Buy rating on CHF Solutions (CHFS – Research Report) yesterday and set a price target of $20.00. The company’s shares closed last Wednesday at $7.94, close to its 52-week low of $5.80.
According to TipRanks.com, Vendetti is a 5-star analyst with an average return of 23.3% and a 52.5% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Milestone Scientific, and Sensus Healthcare.
Currently, the analyst consensus on CHF Solutions is a Moderate Buy with an average price target of $20.00.
Based on CHF Solutions’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.9 million and GAAP net loss of $4.26 million. In comparison, last year the company earned revenue of $1.25 million and had a GAAP net loss of $4.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CHF Solutions, Inc. is a medical device company, which engages in the provision of products for the treatment of fluid overload. Its product include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.